Bitterroot Bio

We have completed enrollment in our Phase 1 study of BRB-002 in healthy volunteers. Topline findings are expected in early 2025, and we are excited to begin our Phase 2 proof-of-concept trial in patients with atherosclerosis in 2025. A huge thanks to our participants, teams, and partners for making this possible!  Learn more by reading our press release here: https://lnkd.in/efuUETTb #BitterrootBio #NucleusNetwork #Novotech #360biolabs #BRB002 #heartdisease #cardiovascular #drugdevelopment

It is always a gift to hear an extraordinary leader share the motivation and focus it takes to drive success. Bitterroot Bio’s CEO, Pavan Cheruvu, shared his inspiring journey, with a learned and critical focus on talent and culture, on the Biotech 2050 podcast. What struck us the most is Pavan’s deep sense of responsibility, and keeping a keen eye on the north star of what we are working to accomplish. Now more than ever, it’s important for us to listen to leaders who remind us that with the right blend of scientific assets, mission driven team, supportive investors and a positive and dynamic company culture we have the opportunity to transform lives in life sciences.   Listen here: https://lnkd.in/gp9M_BNZ #CardioImmunology #HeartHealth #BitterrootBio #Innovation #Leadership

A heartfelt thank you to the American Heart Association for their unwavering commitment to advancing research and advocacy in cardiovascular health. It’s an honor to be part of the Bay Area Legacy Circle—a community that not only cares deeply about the future of CVD treatment and prevention but actively supports it. With World Heart Day approaching on September 29th, it’s a perfect reminder of the power of community, collaboration, and shared purpose in tackling cardiovascular disease. We are grateful to be part of a community making a difference in the future of CVD.💙 #WorldHeartDay #ThankYouAHA #CVDCommunity #BayAreaLegacyCircle

Honored to represent Bitterroot Bio as I joined colleagues from across biotech at the Mass General World Medical Innovation Forum for a terrific panel discussion about the impact of metabolic therapies on cardiovascular and neurologic diseases. Thank you Patrick Ellinor and Jason Zemansky for moderating a wonderful conversation. The panel can be replayed at https://lnkd.in/eXvzEPsf online. #wmif #bitterrootbio #metabolism #heartdisease #atherosclerosis #drugdevelopment

On Tuesday, September 24th our CMO Craig Basson, MD, PhD, will join a distinguished panel at the 2024 World Medical Innovation Forum. Together, these industry leaders will delve into “The Innovation Gap: The Broader Impact of Metabolic Drugs on Related Diseases”. Don’t miss the insights from this thought-provoking discussion! Learn more about the #WMIF2024 here: https://lnkd.in/e_tAiS_p #innovation #cardioimmunology #bitterrootbio

On Global Running Day, we were inspired to celebrate our love of running by lacing up together and supporting the AHA with every mile. Here’s to healthier hearts!  #GlobalRunningDay #HealthyHearts #RunWithTheWorld #CVD #BitterrootBio

Join us in welcoming Sherwin C. as our new Chief Legal Officer and Corporate Secretary! Read more about new team members here: https://lnkd.in/eynqN_Bc #WeAreBitterroot #CardioImmunology #BitterrootBio #Leadership

We are thrilled that our Bitterroot Bio website won a Web Excellence Award! 🌟 With over 950 entries from 27 countries, we are honored. Check out the award announcement for Life Sci Communications here: https://lnkd.in/eqtpMHqr #WebExcellenceAwards #WebDesign #LifeSci #BitterrootBio

We’re thrilled to see that our team had a productive visit to Australia where the first participants have been dosed in a first-in-human Phase 1 trial of BRB-002! #BitterrootBio #clinicaltrials #australia #cardiovascular #immunology #heartdisease

We are delighted to share our co-founder, Nicholas Leeper's latest publication in Nature Reviews on cardiovascular disease, highlighting dysfunctional efferocytosis as a key driver of atherosclerosis and exploring therapeutic strategies like targeting the CD47–SIRPα axis. This remarkable work ties back to our innovative efforts at Bitterroot Bio to advance cardiovascular health. Congratulations, Nick! 🎉  Read more here: https://lnkd.in/eqpEhzNz